Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to verify non-inferiority of survival time between
Isovorin/5-fluorouracil (1-LV/5FU) therapy and TS-1 therapy in patients with inoperable
advanced or recurrent gastric cancer. Secondary endpoints include response rates, duration of
responses, time to progression (TTP) safety and quality of life (QOL).